# Novartis completes $2B acquisition of Endocyte

Novartis AG completed its acquisition of Endocyte Inc. for $24 per share in cash, totaling approximately $2 billion. The deal was originally announced on October 17, 2018.

- Type: Acquisition
- Announced: 2018-12-20
- Where: United States
- Value: $2.00B
- Status: completed
- Products: pharmaceuticals (cancer treatments)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Novartis](https://endata.com/companies/32041.md) (acquirer)
- [Endocyte](https://endata.com/companies/32999.md) (target)

## Sources

- [uk.marketscreener.com](https://uk.marketscreener.com/quote/stock/NOVARTIS-AG-9364983/news/Novartis-AG-completed-the-acquisition-of-Endocyte-Inc-from-Blue-Chip-Venture-Company-Ltd-Sanderl-34472763/), 2018-12-20: "Novartis AG completed the acquisition of Endocyte Inc."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.